Can Brazil play a more important role in global tuberculosis drug production? An assessment of current capacity and challenges
Bibliographic Data
| ID | 15375333 |
|---|---|
| Authors | André Luis Gemal (Universidade Federal do Rio de Janeiro), Andre Gemal, Joel Keravec, Alexandre Menezes, Anete Trajman (0000-0002-4000-4984, McGill University, corresponding author) |
| Year | 2013 |
| Volume | 13 |
| Issue | 1 |
| Pages | 279-279 |
| Publication date | 2013-03-27 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | BMC Public Health (JOURNAL) |
| Journal identifiers | ISSN: 1471-2458 • E-ISSN: 1471-2458 |
| Publisher | BioMed Central (PUBLISHER • GB) |
| DOI | 10.1186/1471-2458-13-279 |
| PMID | 23537151 |
| PMCID | PMC3645962 |
| OpenAlex | W2166947801 |
| Language | EN |
| References cited | 12 |
International manufacturers of raw material for tuberculosis treatment should undergo certification and pre-qualify their active pharmaceutical ingredients as a first step to ensure quality of tuberculosis drugs. At the country level, Brazilian public manufacturers should apply for international certification and tuberculosis drugs should be pre-qualified by international organisms. Finally, only with political commitment and large-scale production will Brazilian public sector manufacturers be able to partially supply the global market
Certification · Environmental health · Public health · Quality (philosophy · Risk analysis (engineering · Tuberculosis · Biotechnology and Related Fields · Global Health and Surgery · Medicine · Tuberculosis Research and Epidemiology
The Brazilian health system
Drug development for neglected diseases
Assistência farmacêutica no sistema público de saúde no Brasil
Gasto do Ministério da Saúde com medicamentos
Duas décadas de pesquisa em tuberculose no Brasil
A produção pública de medicamentos no Brasil
A política brasileira de distribuição e produção de medicamentos anti-retrovirais
| Citation velocity | historical |
|---|---|
| Highly cited | No |